Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome
Sponsor: NYU Langone Health
Listed as NCT04009148, this observational or N/A phase trial focuses on BRCA-Mutated Ovarian Carcinoma and BRIP1 Gene Mutation and remains ongoing. Sponsored by NYU Langone Health, it has been updated 13 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Jul 2025 — Present [monthly]
Active Not Recruiting
-
Sep 2024 — Jul 2025 [monthly]
Active Not Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting
-
Feb 2024 — Jul 2024 [monthly]
Recruiting
▶ Show 8 earlier versions
-
Apr 2023 — Feb 2024 [monthly]
Recruiting
-
May 2022 — Apr 2023 [monthly]
Recruiting
-
Dec 2021 — May 2022 [monthly]
Recruiting
-
Jun 2021 — Dec 2021 [monthly]
Recruiting
-
Jan 2021 — Jun 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Jul 2020 — Nov 2020 [monthly]
Recruiting
-
Aug 2019 — Jul 2020 [monthly]
Recruiting
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NYU Langone Health
For direct contact, visit the study record on ClinicalTrials.gov .